证券代码：300119 证券简称：瑞普生物 公告编号：2024-032 天津瑞普生物技术股份有限公司 关于回购注销 2022 年限制性股票激励计划 部分限制性股票的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 天津瑞普生物技术股份有限公司（以下简称"公司"）于 2024 年 6 月 11 日 召开的第五届董事会第十五次（临时）会议及第五届监事会第十二次（临时）会 议审议通过了《关于回购注销 2022 年限制性股票激励计划部分限制性股票的议 案》《关于调整 2022 年限制性股票激励计划回购价格的议案》《关于修改公司 章程的议案》，相关议案尚需提交公司股东大会审议，现将回购注销有关事项说 明如下： 一、股权激励计划已履行的相关审批程序 （一）2022 年 4 月 28 日，公司第四届董事会第三十八次会议审议通过了 《关于<公司 2022 年限制性股票激励计划(草案)>及其摘要的议案》《关于<公司 2022 年限制性股票激励计划实施考核管理办法>的议案》《关于提请公司股东大 会授权董事会办理 2022 年限制性股票激励计划相关事宜的议案》，公司第四届 监事 ...

Investment Rating - The report maintains a "Buy" rating for the company, predicting that the stock price will outperform the Shanghai Composite Index by 15% or more within six months [38] Core Views - The company is a leader in China's animal health industry, with a diversified business portfolio and strong growth in revenue and net profit [39][40] - The company's pet business, particularly its cat triple vaccine, has entered a harvest period, breaking the long-term reliance on imported vaccines [3][5][159] - The company's synthetic biology business is expected to benefit from policy support and technological advancements, with significant growth potential [186][187] Business Segments Animal Health Products - The company's animal health products, including vaccines and pharmaceuticals, are the main revenue drivers, with a stable market share in the poultry sector [148][149] - The company has signed strategic agreements with major poultry farming companies, ensuring stable sales and market expansion [154][155] - The company's pig vaccine business is expected to benefit from the recovery of pig prices and increased demand due to industry consolidation [134][156] Pet Business - The company's pet business has seen significant growth, particularly with the launch of its cat triple vaccine, which has achieved rapid market penetration [5][159][170] - The cat triple vaccine market in China is expected to grow significantly, with the company well-positioned to capture market share due to its early entry and competitive pricing [7][164] Synthetic Biology - The company has entered the synthetic biology sector, leveraging its partnerships with research institutions and policy support to develop new products in animal health and feed additives [186][187] - The synthetic biology market is expected to grow rapidly, with the company focusing on cost-effective protein production and other innovative applications [11][120] Market Outlook - The pet vaccine market in China is expected to grow significantly, driven by increasing pet ownership and higher vaccination rates [7][164] - The synthetic biology sector is poised for rapid growth, with the company well-positioned to benefit from technological advancements and policy support [11][120] - The animal health industry is expected to see increased consolidation, with the company likely to benefit from its strong market position and diversified product portfolio [79][92]

请仔细阅读在本报告尾部的重要法律声明 2 少数股东权益 309 358 421 497 股东权益合计 4,805 5,172 5,843 6,640 负债和股东权益合计 6,596 6,979 7,775 8,726 资料来源：公司公告，华西证券研究所 证券研究报告|公司点评报告 财务报表和主要财务比率 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | |------------------------------------|-------|-------|-------------------------|-------|-------------------------------|-------|-------|-------------------------|-------| | [Table_Finance] 利润表（百万元） | | | 2023A 2024E 2025E 2026E | | 现金流量表（百万元） | | | 2023A 2024E 2025E 2026E | | | 营业总收入 | 2,249 | 2, ...

证券代码：300119 证券简称：瑞普生物 公告编号：2024-028 天津瑞普生物技术股份有限公司 2023 年度权益分派实施公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 特别提示： 1、天津瑞普生物技术股份有限公司（以下简称"公司"、"本公司"）通 过回购专用证券账户持有的公司股份 3,689,608 股不享有利润分配权利。因此， 本次实际现金分红总额=实际参与现金分红的股本×分配比例=462,586,578 股× 0.4000000 元/股=185,034,631.20 元。 2、本次权益分派实施后计算除权除息价格时，按公司总股本（含回购股份） 折算每股现金分红（含税）=本次实际现金分红总额/公司总股本=185,034,631.20 元/466,276,186 股=0.3968348 元/股。本次权益分派实施后的除权除息参考价=除 权除息前一交易日收盘价-按公司总股本折算每股现金分红=除权除息日前一交 易日收盘价-0.3968348 元/股。 公司 2023 年度权益分派方案已经 2024 年 4 月 19 日召开的 2023 年年度股 东大会审 ...

深圳 邮箱：yanjiusuo@cnpsec.com 地址：深圳市福田区滨河大道 9023 号国通大厦二楼 邮编：518048 -41% -37% -33% -29% -25% -21% -17% -13% -9% -5% -1% 2023-05 2023-07 2023-09 2023-12 2024-02 2024-04 瑞普生物 农林牧渔 个股表现 2024 年 5 月 6 日 证券研究报告：农林牧渔 | 公司点评报告 SAC 登记编号:S1340522100001 Email:wangqi2022@cnpsec.com 股票投资评级 买入|首次覆盖 资料来源：聚源，中邮证券研究所 | --- | --- | |-----------------------------------------------------|---------------------| | | | | 公司基本情况 | | | 最新收盘价（元） | 16.39 | | 总股本 / 流通股本（亿股） 总市值 / 流通市值（亿元） | 4.66 / 3.34 76 / 55 | | 52 周内最高 / 最低价 | 21.28 / ...

[ T able_StockInfo] 2024 年 04 月 29 日 证券研究报告•2024 年一季报点评 买入 （维持） 当前价：15.51 元 瑞普生物（300119）农林牧渔 目标价：——元（6 个月） [Table_Summary 业绩总结：公司发布 ] 2024 年一季度报告，2024Q1 实现营业收入 5.33 亿元， 同比+20.42%，实现归母净利润 0.88亿元，同比+8.35%，扣非归母净利润 0.77 亿元，同比+20.84%。 点评：一季度开局良好，利润质量提升。2024年一季度，公司在养殖业仍处于 亏损阶段实现盈利同比正增长，我们认为主要系公司大客户战略效果明显及猫 三联疫苗贡献营收及利润增量。报告期内，公司自主研发的猫三联疫苗"瑞喵 舒"正式推向市场，实现销售收入 1200 万元，打破进口产品在我国的垄断。 制剂及原料药业务实现销售收入 10.84亿元，同比增长 11.20%。禽用生物制品 业务实现销售收入 9.28亿元，同比增长 3.64%，畜用生物制品业务实现销售收 入 1.41亿元，同比增长 8.47%。持续建立与大型养殖集团战略合作，畜禽板块 步入高速增长期。宠物板块， ...

证券代码：300119 证券简称：瑞普生物 公告编号：2024-027 天津瑞普生物技术股份有限公司 统一社会信用代码：91130600MA0E80B2X5 住所：河北省保定市莲池区百楼镇锦湖北大街京东(保定)数字产业园 2 号楼 316 室商用 法定代表人：姚丽丽 关于收购保定市收骏科技有限公司100%股权进展暨 完成工商变更登记的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 一、交易概述 天津瑞普生物技术股份有限公司（以下简称"公司"）于 2024 年 3 月 28 日 召开第五届董事会第十三次会议、第五届监事会第十次会议，审议通过了《关于 收购保定市收骏科技有限公司 100%股权暨关联交易的议案》，同意公司以自有资 金或自筹资金 2.30 亿元收购保定市收骏科技有限公司（以下简称"保定收骏"） 100%股权。本议案已经 2024 年 4 月 19 日召开的 2023 年年度股东大会审议通过。 具体内容详见公司在巨潮资讯网披露的《关于收购保定市收骏科技有限公司 100% 股权暨关联交易的公告》《2023 年年度股东大会决议公告》（公告编号：2024 ...

| --- | --- | |--------------|-------------------------------------------| | | | | | | | 研究所： | | | 证券分析师： | 程一胜 S0350521070001 | | | chengys01@ghzq.com.cn | | 证券分析师： | 熊子兴 S0350522100002 xiongzx@ghzq.com.cn | 最近一年走势 相关报告 《瑞普生物（300119）2023 年三季报点评：业绩 稳步增长，坚持研发驱动（买入）*动物保健Ⅱ*程 一胜，熊子兴》——2023-10-27 《瑞普生物（300119）2023 年半年报点评：主营 业务稳中有进，积极打造宠物第二增长曲线（买入） *动物保健Ⅱ*程一胜，熊子兴》——2023-08-28 风险提示 畜禽价格大幅下降风险、重大动物疫病风险、新产品 上市不及预期、行业竞争加剧、宠物药品及疫苗销售不及预期等。 2024 年 4 月 25 日，瑞普生物发布 2024 年一季报：2024Q1 公司实现营 业收入 5.33 亿元，同比+20.42%，实现归母净利润 0.8 ...

Financial Performance - The company's revenue for Q1 2024 was ¥533,199,134.68, representing a 20.42% increase compared to ¥442,780,482.14 in the same period last year[5] - Net profit attributable to shareholders was ¥87,571,107.92, an increase of 8.35% from ¥80,823,461.46 in the previous year[5] - The basic earnings per share increased by 9.13% to ¥0.1901 from ¥0.1742 year-on-year[5] - Net profit for Q1 2024 was ¥93,504,682.67, representing a 6.4% increase from ¥87,502,825.62 in Q1 2023[30] - Earnings per share (EPS) for Q1 2024 was ¥0.1901, compared to ¥0.1742 in the previous year, reflecting a growth of 14.0%[31] - The company reported a total comprehensive income of ¥93,504,682.67 for Q1 2024, compared to ¥87,502,825.62 in the same period last year[31] Cash Flow - The net cash flow from operating activities surged by 205.13%, reaching ¥89,135,929.23 compared to ¥29,212,171.85 in the prior year[5] - Cash inflow from operating activities totaled ¥547,363,142.82, an increase from ¥489,240,423.96 in the same quarter last year[33] - The net cash flow from operating activities for Q1 2024 was ¥89,135,929.23, a significant increase from ¥29,212,171.85 in Q1 2023, reflecting a growth of approximately 205%[34] - The company reported a net increase in cash and cash equivalents of ¥279,916,691.96 for Q1 2024, contrasting with a net decrease of ¥54,701,596.71 in Q1 2023[35] - The cash inflow from borrowing activities was ¥204,000,000.00, an increase from ¥125,600,000.00 in the previous year, marking a growth of approximately 62%[34] Assets and Liabilities - Total assets at the end of the reporting period were ¥6,664,480,174.79, a 1.04% increase from ¥6,595,941,501.08 at the end of the previous year[5] - The company's total current assets reached RMB 3.379 billion, compared to RMB 3.263 billion at the beginning of the period, reflecting a growth of approximately 3.54%[25] - The company's total liabilities decreased from RMB 1.791 billion to RMB 1.780 billion, indicating a reduction of about 0.62%[26] - The company's cash and cash equivalents increased to RMB 617.35 million from RMB 335.40 million, representing a growth of approximately 84.06%[24] Shareholder Information - The total number of common shareholders at the end of the reporting period is 18,265[12] - The largest shareholder, Li Shoujun, holds 35.92% of the shares, totaling 167,474,479 shares, with 125,605,859 shares pledged[12] - The percentage of shares held by the top ten shareholders accounts for a significant portion of the company's equity, indicating concentrated ownership[12] Research and Development - The company continues to focus on research and development to enhance its product offerings and market position[15] - Research and development expenses amounted to ¥36,418,931.94, up 13.8% from ¥32,060,179.48 in Q1 2023[28] - The company obtained four new veterinary drug registration certificates during the reporting period, enhancing its capabilities in livestock and pet health[15] - The company successfully launched the cat trivalent vaccine "Rui Miao Shu," which is the first domestic vaccine to pass emergency evaluation and obtain a temporary approval number from the Ministry of Agriculture and Rural Affairs[17] - The company signed a cooperation development agreement for the cat HCPC quadrivalent mRNA vaccine with Jiangsu Shenji Biotechnology Co., focusing on developing vaccines for multiple feline diseases[18] Future Plans and Strategies - The company plans to continue expanding its market presence and investing in new product development to drive future growth[5] - The company aims to create maximum value for customers through competitive products and services, reflecting its global vision and industry perspective[15] Financial Adjustments and Compliance - The company announced delays in certain fundraising projects, adjusting the expected completion dates for two projects to December 31, 2024, and December 31, 2026, respectively[21] - The company did not undergo an audit for the Q1 2024 report, as indicated in the financial statements[36] - The company has adopted new accounting standards starting from 2024, which may impact future financial reporting[36]

证券代码：300119 证券简称：瑞普生物 天津瑞普生物技术股份有限公司投资者关系活动记录表 编号：2024-003 | | 分析师会议 □ 特定对象调研 □ | | --- | --- | | 投资者关系活动 | □ 媒体采访 √ 业绩说明会 | | | □ 新闻发布会 □ 路演活动 | | 类别 | □ 现场参观 | | | 其他 □ | | | 中金公司、国联证券、华泰证券、天风证券、中信证券、太平洋 证券、中国人民养老保险、新华养老保险、建信基金、华夏基金、 | | 参与单位名称 | | | | 中邮基金、天治基金、英大保险资管、上汽颀臻资管、华能贵诚 | | | 信托及线上投资者。 | | 时间 | 2024 年 4 月 23 日 (周二) 15:00-17:00 | | 地点 | 中国证券报·中证网路演中心 | | | 董事长 李守军 | | | 独立董事 周睿 | | 上市公司接待人 | 保荐代表人 银河证券 郭玉良 | | 员姓名 | 财经负责人 吴艳敏 | | | 董事会秘书 谢刚 | | | 一、董事长致辞及 2023 年度业绩介绍 | | | 2023 年养殖行业遭遇了低价亏损寒潮的袭击 ...